Can Intravesical BCG Cause Renal Failure?
Yes, intravesical BCG can cause acute kidney injury and renal failure, though this is a rare but serious complication that requires immediate recognition and treatment.
Mechanism and Clinical Presentation
Intravesical BCG can cause renal injury through two primary mechanisms:
- Immune-mediated hypersensitivity reaction leading to acute tubulointerstitial nephritis (ATIN), which is the most common renal manifestation 1, 2
- Hematogenous dissemination of BCG organisms, particularly after traumatic instillation, causing systemic infection with renal involvement 3, 4
The renal injury typically presents as acute tubulointerstitial nephritis with or without granulomatous changes, though mesangial glomerulonephritis has also been reported 3.
Timing and Risk Factors
Critical pitfall: Renal complications can occur as early as after the first BCG instillation, contrary to older literature suggesting this only happens after multiple treatments 1. A recent 2024 case report documented severe acute kidney injury (GFR dropping to 4 ml/min/1.73 m²) occurring just two days after the first IVBCG administration 1.
The FDA drug label acknowledges systemic complications but does not specifically detail renal failure as a common adverse event 5. However, the label does note that "symptoms such as fever of 103°F or greater, or acute localized inflammation persisting longer than 2–3 days suggest active infections" 5.
Clinical Recognition
Monitor for these warning signs after each BCG instillation:
- Rising serum creatinine (≥26 μmol/L or ≥0.3 mg/dL increase)
- Decreased urine output
- Proteinuria, leukocyturia, and hematuria
- Persistent fever (>103°F) beyond 2-3 days
- Systemic symptoms beyond typical "flu-like" syndrome that resolves in 24-48 hours 1
Laboratory findings in documented cases include hyperkalemia, metabolic acidosis, elevated inflammatory markers, and significant proteinuria (up to 900 mg/24h) 1.
Progressive Kidney Disease Risk
Important consideration: Beyond acute kidney injury, there is emerging evidence of "repetitive" immune-mediated renal injury presenting as progressive chronic kidney disease (CKD) rather than isolated AKI episodes 2. One case demonstrated that renal function plateaued when BCG was held and worsened when reinstilled, ultimately progressing to advanced CKD (eGFR 10 ml/min/1.73 m²) 2.
Management Algorithm
When BCG-induced renal injury is suspected:
Immediately discontinue BCG therapy - renal function may stabilize when BCG is held 2
Consult infectious disease and nephrology specialists without delay 5
Initiate empiric treatment before culture results:
Provide supportive care:
- Hemodialysis if severe AKI develops 1
- Manage electrolyte abnormalities and metabolic acidosis
Monitor closely: Check creatinine after each subsequent BCG treatment if therapy is resumed 1
Prognosis
Renal recovery is variable and often only partially reversible 3. In documented cases:
- Some patients show significant improvement with treatment (creatinine improving from >10 mg/dL to 2.04 mg/dL within 2 weeks) 1
- Others develop irreversible chronic kidney disease despite intervention 2
- Early recognition and prompt corticosteroid therapy may prevent progression to end-stage renal disease 2
Surveillance Recommendations
Essential monitoring protocol (not explicitly stated in major guidelines 6, 7 but critical based on case evidence):
- Measure serum creatinine before each BCG instillation and 1-2 weeks after
- Perform urinalysis if any systemic symptoms develop
- Maintain high clinical suspicion, as this complication is likely under-recognized due to low awareness 2
The major bladder cancer guidelines from NCCN and ESMO extensively discuss BCG efficacy and common side effects but do not specifically address renal complications 6, 7, highlighting a gap in guideline coverage that necessitates increased awareness among both urologists and nephrologists.